Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.

Literature DB >> 29858173

Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.

Jean-Marie Michot^1,2, Mathilde Fusellier¹, Stephane Champiat^1,3, Charles Velter⁴, Capucine Baldini^1,3, Anne-Laure Voisin⁵, Francois-Xavier Danlos¹, Yolla El Dakdouki¹, Maxime Annereau⁶, Xavier Mariette⁷, Caroline Robert⁴, Khadija Cherif⁸, Aurélien Marabelle¹, Christine Mateus⁴, Olivier Lambotte^2,3,9,10.

Abstract

Entities: Disease

Keywords: autoimmunity; multidisciplinary team care; systemic lupus erythematosus

Mesh：

Substances：
Immunologic Factors

Year: 2018 PMID： 29858173 DOI： 10.1136/annrheumdis-2018-213677

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

Review 1. The relationships between cancer and autoimmune rheumatic diseases.

Authors: Laura C Cappelli; Ami A Shah
Journal: Best Pract Res Clin Rheumatol Date: 2020-02-03 Impact factor: 4.098

Review 2. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors: Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal: Drug Saf Date: 2019-02 Impact factor: 5.606

Review 3. Cutaneous Lupus Erythematosus: Progress and Challenges.

Authors: Amy J Petty; Lauren Floyd; Christopher Henderson; Matilda W Nicholas
Journal: Curr Allergy Asthma Rep Date: 2020-04-04 Impact factor: 4.806

Review 4. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.

Authors: Laura C Cappelli; Clifton O Bingham
Journal: Arthritis Rheumatol Date: 2021-03-05 Impact factor: 10.995

5. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.

Authors: Xionghao Pang; Juanjuan Qian; Hua Jin; Lei Zhang; Lin Lin; Yuli Wang; Yi Lei; Zeqiang Zhou; Meixiang Li; Henghui Zhang
Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751

10. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.

Authors: Alessandra Ferro; Angela Filoni; Alberto Pavan; Giulia Pasello; Valentina Guarneri; PierFranco Conte; Mauro Alaibac; Laura Bonanno
Journal: Front Med (Lausanne) Date: 2021-06-04

Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.

Review 1. The relationships between cancer and autoimmune rheumatic diseases.

Review 2. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Review 3. Cutaneous Lupus Erythematosus: Progress and Challenges.

Review 4. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.

5. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.

Review 6. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

7. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.

8. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

9. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

10. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.